Literature DB >> 22743124

Revision total hip arthroplasty using a modular femoral implant in Paprosky type III and IV femoral bone loss.

Rasesh R Desai1, Arthur L Malkani, Kirby D Hitt, Fredrick F Jaffe, John R Schurman, Jianhua Shen.   

Abstract

The purpose of this study was to compare results of patients with Paprosky type I and II femoral defects vs type IIIA, IIIB, and IV defects in patients undergoing revision hip arthroplasty. There were 64 patients in the group with type I and II defects with an average age of 68 years. There were 52 patients with Paprosky type IIIA, IIIB, and IV defects with an average age of 67 years. There were 8 intraoperative fractures in the type III and IV group, whereas there were 9 in the type I and II group. There were no differences between the 2 groups with respect to subsidence, loosening, dislocation, infection, and medical complications. Survivorship for the whole group was 96.9% at 5 years. Modular femoral implants provide several intraoperative options to restore leg length, offset, and stability despite femoral defects. We did not realize a higher failure rate in patients with type III or IV defects.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22743124     DOI: 10.1016/j.arth.2012.03.039

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  3 in total

1.  Can machine learning models predict failure of revision total hip arthroplasty?

Authors:  Christian Klemt; Wayne Brian Cohen-Levy; Matthew Gerald Robinson; Jillian C Burns; Kyle Alpaugh; Ingwon Yeo; Young-Min Kwon
Journal:  Arch Orthop Trauma Surg       Date:  2022-05-04       Impact factor: 3.067

2.  Technical Note for Transfemoral Implantation of Tapered Revision Stems. The Advantage to Stay Short.

Authors:  Bernd Fink
Journal:  Arthroplast Today       Date:  2021-04-24

3.  Long-term outcomes of cementless femoral stem revision with the Wagner cone prosthesis.

Authors:  Kyung-Soon Park; Sheng-Yu Jin; Jun-Hyuk Lim; Taek-Rim Yoon
Journal:  J Orthop Surg Res       Date:  2021-06-11       Impact factor: 2.359

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.